Drug Profile
Cirtuvivint - Biosplice Therapeutics
Alternative Names: SM-08502Latest Information Update: 18 Jul 2023
Price :
$50
*
At a glance
- Originator Samumed
- Developer Biosplice Therapeutics
- Class Amides; Antineoplastics; Isoquinolines; Piperazines; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action DYRK kinase inhibitors; Wnt signalling pathway modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Colorectal cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
- Preclinical Haematological malignancies
Most Recent Events
- 09 Sep 2022 Preliminary pharmacokinetics, pharmacodynamics, safety and efficacy data from phase I and Ib trial in Solid tumors presented at the 47th European Society for Medical Oncology Congress (ESMO-2022)
- 08 Apr 2022 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 113th Annual Meeting of the American Association for Cancer Research 2022 (AACR-2022)
- 27 Jan 2022 Biosplice Therapeutics and Epic Sciences enters into a clinical trial collaboration for Cirtuvivint for Cancer